Department of Experimental Orthopaedics, Orthopaedic University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
Int J Cancer. 2010 Oct 15;127(8):1804-12. doi: 10.1002/ijc.25205.
Giant cell tumors are heterogeneous tumors consisting of multinucleated giant cells, fibroblast-like stromal cells and mononuclear histiocytes. The stromal cells have been identified as the neoplastic cell population, which promotes the recruitment of histiocytes and the formation of giant cells. Strong evidence exists that these cells develop from mesenchymal stem cells (MSCs) but little is known about the molecular mechanisms involved in GCT tumorigenesis. The aim of our study was the identification of cancer-related genes differentially expressed in GCTs compared to MSCs in order to identify possible targets for aberrant promoter methylation, which may contribute to MSC transformation and GCT development. Gene expression of 440 cancer-related genes was analyzed by DNA microarrays in GCT stromal cells and bone marrow-derived MSCs (BMSCs) isolated from the same patient (n = 3) to avoid interindividual variations. Differential expression was identified for 14 genes, which could be confirmed by quantitative PCR in further 21 GCT and 10 BMSC samples. The most pronounced difference in gene expression was detected for UCHL1, an important regulator of the ubiquitin proteasome pathway. Methylation-specific PCR and bisulfite sequencing revealed a strong methylation of the CpG island covering the UCHL1 promoter in GCT stromal cells, whereas methylation was completely absent in BMSCs. UCHL1 expression in stromal cells could be restored by the methylation inhibitor 5-aza-dC. These data demonstrate that the UCHL1 gene is inactivated in GCTs but not in MSCs, suggesting a possible role of UCHL1 in MSC transformation and GCT development.
巨细胞瘤是一种异质性肿瘤,由多核巨细胞、成纤维样基质细胞和单核组织细胞组成。基质细胞已被鉴定为肿瘤细胞群体,它促进组织细胞的募集和巨细胞的形成。有强有力的证据表明,这些细胞来源于间充质干细胞(MSCs),但对于 GCT 肿瘤发生过程中涉及的分子机制知之甚少。我们的研究目的是鉴定与 GCT 相比在 MSC 中差异表达的癌症相关基因,以确定异常启动子甲基化的可能靶点,这可能有助于 MSC 转化和 GCT 发展。通过 DNA 微阵列分析了 440 个癌症相关基因在 GCT 基质细胞和从同一患者(n = 3)分离的骨髓来源的 MSC(BMSCs)中的基因表达,以避免个体间的差异。在进一步的 21 个 GCT 和 10 个 BMSC 样本中,通过定量 PCR 确认了 14 个基因的差异表达。基因表达的最显著差异是UCHL1 ,它是泛素蛋白酶体途径的重要调节剂。甲基化特异性 PCR 和亚硫酸氢盐测序显示,UCHL1 启动子的 CpG 岛在 GCT 基质细胞中强烈甲基化,而在 BMSCs 中完全没有甲基化。基质细胞中 UCHL1 的表达可以通过甲基化抑制剂 5-aza-dC 恢复。这些数据表明,UCHL1 基因在 GCT 中失活,但在 MSC 中不失活,提示 UCHL1 可能在 MSC 转化和 GCT 发展中发挥作用。